Analysts Set Radius Health Inc (RDUS) Target Price at $48.14
Radius Health Inc (NASDAQ:RDUS) has been given a consensus rating of “Hold” by the eleven brokerages that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $48.14.
Several brokerages have weighed in on RDUS. Cowen reissued a “hold” rating on shares of Radius Health in a research report on Thursday, October 18th. JPMorgan Chase & Co. dropped their price target on shares of Radius Health from $59.00 to $52.00 and set an “overweight” rating for the company in a research report on Friday, November 2nd. Bank of America dropped their price target on shares of Radius Health from $51.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, July 25th. BidaskClub cut shares of Radius Health from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 13th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $25.00 price target on shares of Radius Health in a research report on Tuesday, August 7th.
Large investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc purchased a new stake in shares of Radius Health in the 2nd quarter worth about $162,000. Pacer Advisors Inc. purchased a new stake in shares of Radius Health in the 3rd quarter worth about $186,000. Verition Fund Management LLC purchased a new stake in shares of Radius Health in the 3rd quarter worth about $208,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Radius Health in the 1st quarter worth about $213,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Radius Health in the 3rd quarter worth about $264,000.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.26) by $0.17. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. The company had revenue of $27.70 million during the quarter, compared to analysts’ expectations of $26.00 million. During the same quarter in the prior year, the company earned ($1.31) EPS. The firm’s revenue was up 105.2% on a year-over-year basis. On average, equities research analysts forecast that Radius Health will post -5.17 earnings per share for the current fiscal year.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Article: Capital Gains
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.